Evaluation of cocktail approach to standardise Caco-2 permeability experiments

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 64, Issue 3, 2006, Pages 379-387

  Koljonen, Maija ^a   Hakala, Kati S ^a   Ahtola Sätilä, Tuula ^a   Laitinen, Leena ^a   Kostiainen, Risto ^a   Kotiaho, Tapio ^a   Kaukonen, Ann Marie ^a   Hirvonen, Jouni ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Caco 2 monolayers; Drug permeability; n in one cocktail; Standardisation; Transport mechanism

Indexed keywords

CELL MARKER; FLUORESCEIN; GLYCOPROTEIN P; HYDROCHLOROTHIAZIDE; KETOPROFEN; MANNITOL; METOPROLOL; PHENAZONE; RANITIDINE; VERAPAMIL;

ARTICLE; BATCH CELL CULTURE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CELL TRANSPORT; CONTROLLED STUDY; DRUG PENETRATION; DRUG TRANSPORT; EVALUATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULE; PH; RELIABILITY; STANDARDIZATION;

BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CELL CULTURE TECHNIQUES; CELL MEMBRANE PERMEABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIFFUSION; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; PHARMACEUTICAL PREPARATIONS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 33750039175     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.06.006     Document Type: Article

References (49)

1. FDA Guidance for industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, Food and drug administration, Baltimore, MD, USA, 2000. http://www.fda.gov/cder/guidance/3618fnl.htm.
2. Amidon G.L., Lennernäs H., Shah V.P., and Crison J.R. A theoretical bases for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
3. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175 (1991) 880-885
4. Artursson P., Palm K., and Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 22 (1996) 67-84
5. Bu H., Poglod M., Micetich R., and Khan J. High-throughput Caco-2 cell permeability screening by cassette dosing and sample pooling approaches using direct injection/on-line guard cartridge extraction/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 14 (2000) 523-528
6. Markowska M., Oberle R., Juzwin S., Hsu C., Gryszkiewicz M., and Streeter A.J. Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. J. Pharmacol. Toxicol. Methods 46 (2001) 51-55
7. Tannergren C., Langguth P., and Hoffmann K.-J. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. Pharmazie 56 (2001) 337-342
8. Larger P., Altamura M., Catalioto R.-M., Giuliani S., Maggi C.A., Valenti C., and Triolo A. Simultaneous LC-MS/MS determination of reference pharmaceuticals as a method for the characterization of the Caco-2 cell monolayer absorption properties. Anal. Chem. 74 (2002) 5273-5281
9. Hakala K.S., Laitinen L., Kaukonen A.M., Hirvonen J., Kostiainen R., and Kotiaho T. Development of LC/MS/MS methods for cocktail dosed Caco-2 samples using atmospheric pressure photoionization and electrospray ionization. Anal. Chem. 75 (2003) 5969-5977
10. Laitinen L., Kangas H., Kaukonen A.M., Hakala K., Kotiaho T., Kostiainen R., and Hirvonen J. N-in-One permeability studies of heterogeneous sets of compounds across Caco-2 cell monolayers. Pharm. Res. 20 (2003) 187-197
11. Balimane P.V., Patel K., Marino A., and Chong S. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur. J. Pharm. Biopharm. 58 (2004) 99-105
12. Palmgren J.J., Mönkkönen J., Jukkola E., Niva S., and Auriola S. Characterization of Caco-2 cell monolayer drug transport properties by cassette dosing using UV/fluorescence HPLC. Eur. J. Pharm. Biopharm. 57 (2004) 319-328
13. Marino A.M., Yarde M., Patel H., Chong S., and Balimane P.V. Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. Int. J. Pharm. 297 (2005) 235-241
14. Volpe D.A., Faustino P.J., and Yu L.X. Towards standardization of an in vitro method of drug absorption. Pharmacopeial Forum 27 4 (2001) 2916-2922
15. Volpe D.A., Ciavarella A.B., Asafu-Adjaye E.B., Ellison C.D., J Faustino P., and Yu L.X. AAPS Pharm. Sci. 3 S1 (2001)
16. J.E. Polli, et al., Summary workshop report: biopharmaceutics classification system - implementation challenges and extension opportunities 96 (2004), 1375-1381.
17. Ungell A.-L., and Karlsson J. Cell cultures in drug discovery: an industrial perspective. In: van de Waterbeemd H., Lennernäs H., and Artursson P. (Eds). Drug Bioavailability (2003), Wiley-VCH, Weinheim, Germany 90-131
18. Anderle P., Niederer E., Rubas W., Hilgendorf C., Spahn-Langguth H., Wunderli-Allenspach H., Merkle H., and Langguth P. P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and exposure on P-gp expression levels. J. Pharm. Sci. 87 (1998) 757-762
19. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr. Top. Med. Chem. 1 4 (2001) 277-351
20. Lennernäs H., Palm K., Fagerholm U., and Artursson P. Comparison between active and passive drug transport in human intestinal epithelial (caco-2) cells in vitro and human jejunum in vivo. Int. J. Pharm. 127 (1996) 103-107
21. 2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J. Pharmacol. Exp. Ther. 288 (1999) 171-178
22. Lee K., Ng C., Brouwer K.L.R., and Thakker D.R. Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 303 (2002) 574-580
23. Choi J.-S., Jin M.J., and Han H.-K. Role of monocarboxylic acid transporter in the cellular uptake of NSAIDS. J. Pharm. Pharmacol. 57 (2005) 1185-1189
24. Konishi Y., Hagiwara K., and Shimizu M. Transepithelial transport of fluorescein in Caco-2 cell monolayers and use of such transport in in vitro evaluation of phenolic acid availability. Biosci. Biotechnol. Biochem. 66 (2002) 2449-2457
25. Kuwayama K., Miyauchi S., Tateoka R., Abe H., and Kamo N. Fluorescein uptake by a monocarboxylic acid transporter in human intestinal Caco-2 cells. Biochem. Pharmacol. 63 (2002) 81-88
26. Doppenschmitt S., Spahn-Langguth H., Regårdh C.G., and Langguth P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 88 (1999) 1067-1072
27. Neuhoff S., Ungell A.-L., Zamora I., and Artursson P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res. 20 (2003) 1141-1148
28. Takanaga H., Tamai I., and Tsuji A. pH-dependent and carrier-mediated transport of salicylic-acid across Caco-2 cells. J. Pharm. Pharmacol. 46 (1994) 567-570
29. Ogihara T., Tamai I., Takanaga H., Sai Y., and Tsuji A. Stereoselective and carrier-mediated transport of monocarboxylic acids across Caco-2 cells. Pharm. Res. 13 (1996) 1828-1832
30. Yamashita S., Furubayashi T., Kataoka M., Sakane T., Sezaki H., and Tokuda H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur. J. Pharm. Sci. 10 (2000) 195-204
31. Shiau Y.F., Fernandez P., Jackson M.J., and McMonagle S. Mechanisms maintaining a low-pH microclimate in the intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 248 (1985) G608-G617
32. Polli J., Wring S., Humphreys J., Huang L., Morgan J., Webster L., and Serabjit-Singh C. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299 (2001) 620-628
33. Legen I., and Kristl A. pH and energy dependent transport of ketoprofen across rat jejunum in vitro. Eur. J. Pharm. Biopharm. 56 (2003) 87-94
34. Siissalo S., Laitinen L., Koljonen M., Kortejärvi H., Hirvonen J., and Kaukonen A.M. Vinblastine induced Caco-2 cell line is a promising candidate for in vitro screening of potential P-glycoprotein substrates. LogP 2004 Symposium, Physico-chemical and Biological Profiling in Drug Research (2004), Zürich, Switzerland
35. Siissalo S., Stilgenbauer E., Kurkela M., Vellonen K.S., Urtti A., Yliperttula M., Finel M., Hirvonen J., and Kaukonen A.M. The expression of different efflux proteins and metabolizing enzymes in Caco-2 cell lines determined by RT-PCR. Drug Metab. Rev. 37 Suppl. 1 (2005) 51
36. Palm K., Luthman K., Ros J., Gråsjö J., and Artursson P. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J. Pharmacol. Exp. Ther. 291 (1999) 435-443
37. Taipalensuu J., Tavelin S., Lazorova L., Svensson A.-C., and Artursson P. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur. J. Pharm. Sci. 21 (2004) 69-75
38. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., and Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal epithelial Caco-2 cells. J. Biol. Chem. 268 (1993) 14991-14997
39. Gan L.-S.L., Yanni S., and Thakker D.R. Modulation of the tight junctions of the Caco-2 cell monolayers by H2-antagonists. Pharm. Res. 15 (1998) 53-57
40. Lee K., and Thakker D.R. Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J. Pharm. Sci. 88 (1999) 680-687
41. Gan L.-S., Hsyu P.-H., Pritchard J.F., and Thakker D.R. Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers. Pharm. Res. 10 (1993) 1722-1725
42. Lindmark T., Kimura Y., and Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J. Pharmacol. Exp. Ther. 284 (1998) 362-369
43. Masungi C., Borremans C., Willems B., Mensch J., Van Dijck A., Augustijns P., Brewster M.E., and Noppe M. Usefulness of a novel Caco-2 cell perfusion system. I. in vitro prediction of the absorption potential of passively diffused compounds. J. Pharm. Sci. 93 (2004) 2507-2521
44. Sugano K., Takata N., Machida M., Saitoh K., and Terada K. Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model. Int. J. Pharm. 241 (2002) 241-251
45. Zhu C., Jiang L., Chen T., and Hwang K. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur. J. Med. Chem. 37 (2002) 399-407
46. Palm K., Stenberg P., Luthman K., and Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14 (1997) 568-571
47. Winiwarter S., Bonham N.M., Ax F., Hallberg A., Lennernäs H., and Karlén A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41 (1998) 4939-4949
48. Degim T., Zaimoglu V., Akay C., and Degim Z. pH-metric log K calculations of famotidine, naproxen, nizatidine, ranitidine and salicylic acid. Farmaco 56 (2001) 659-663
49. Hänninen K., Kaukonen A.M., Kankkunen T., and Hirvonen J. Rate and extent of ion-exchange process: the effect of physico-chemical characteristics of salicylate anions. J. Control Release 91 (2003) 449-463